Leveraging their artificial intelligence capabilities for use in healthcare, medical imaging and research company Resonance Health (ASX: RHT) has received CE marking for its fully automated AI liver fat assessment software enabling commercialisation of their tech throughout Europe.

This certification will allow HepaFat-AI to be sold in the European Economic Area, joining recent approvals in both the USA and Australia. Once utilised by medical professionals, HepaFat-AI automatically analyses magnetic resonance imaging (MRI) datasets to assess liver fat in patients. 

Images taken are analysed by the AI to provide doctors with comprehensive understanding of the patient’s liver fat content, including a liver fat distribution map for illustrative purposes.

Validated for all major MRI scanner makes and models, Hepafat-AI will be marketed to a wide range of physicians and radiologists involved in the detection, monitoring and even treatment of fatty liver disease.

The product can also be used to assist in drug trials due to its ability to deliver real-time data. As the company notes, this could be particularly useful for the development of drugs for non-alcoholic steatohepatitis (NASH), a serious and aggressive form of liver disease.

NASH trials require standardised workflows to ensure clinically meaningful data is generated, which is where the automated Hepafat-AI can become particularly useful to researchers.

This is not the first AI-related product release for Resonance Health, after announcing in October 2020 the advancement of a new AI solution for automated alerts for patients with a suspected pulmonary embolism (PE), blood clots that block arteries in the lungs. 

For the Quarter ending 31 December 2020, Resonance Health reported cash receipts of $1 million which represented a 6% increase on their September Quarter.